February 2020 Archives

Latham BioPharm Group adds Dr. Thijs Beuming and expands consulting offering to include In Silico Drug Discovery services.

CAMBRIDGE, MA – February 25, 2020 – Latham BioPharm Group, Inc. (LBG), a premier provider of life science consulting services, today announced the recent addition of Dr. Thijs Beuming to the team to lead In Silico Drug Discovery services.  LBG’s new offering complements existing product development capabilities by providing full service and strategic support for... Read More

Image Description

Watch now! Roundtable Discussion: Cell and Gene Therapies — Keep the Work In-House, or Use a Third Party?

LBG’s Dr. Joseph Rininger, as an industry leader in Cell & Gene Therapies, was invited to participate in a roundtable discussion at BIO International 2019 on this topic.  Questions posed to the panel by BioProcess Insider editor Dan Stanton were:  Is enough manufacturing capacity available? How do companies reduce cost of goods (CoG) and increase manufacturing efficiency? Should a developer build its own capabilities or... Read More